NCT04954521

Brief Summary

The purpose of this study is to observe and explore the effect of single or combined treatment of arotinib on the survival and prognosis of patients with advanced liver cancer in the real world, and to summarize the treatment experience of a wide range of people.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2021

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 17, 2021

Completed
13 days until next milestone

Study Start

First participant enrolled

June 30, 2021

Completed
8 days until next milestone

First Posted

Study publicly available on registry

July 8, 2021

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 5, 2023

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

July 5, 2024

Completed
Last Updated

July 8, 2021

Status Verified

June 1, 2021

Enrollment Period

2 years

First QC Date

June 17, 2021

Last Update Submit

June 29, 2021

Conditions

Liver Neoplasms

Outcome Measures

Primary Outcomes (1)

  • OS

    Overall Survival

    From date of admission until the date of death from any cause, assessed up to 24 months

Secondary Outcomes (1)

  • PFS

    From date of admission until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

Interventions

AnlotinibDRUG

This is an observational study

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with advanced liver cancer

You may qualify if:

  • Age: ≥ 18 years old, male or female;
  • Patients with advanced liver cancer were diagnosed;
  • Patients assessed by doctors to benefit from single or combined treatment of arotinib;
  • Patients volunteered to join the project.

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

People's Hospital of Guangxi Zhuang Autonomous Region

Nanning, Guangxi, 530000, China

RECRUITING

MeSH Terms

Conditions

Liver Neoplasms

Interventions

anlotinib

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesLiver Diseases

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chief physician

Study Record Dates

First Submitted

June 17, 2021

First Posted

July 8, 2021

Study Start

June 30, 2021

Primary Completion

July 5, 2023

Study Completion

July 5, 2024

Last Updated

July 8, 2021

Record last verified: 2021-06

Data Sharing

IPD Sharing
Will not share

Locations

CN(1)